Capricor Therapeutics (CAPR)
(Real Time Quote from BATS)
$7.61 USD
-0.06 (-0.78%)
Updated Aug 6, 2025 11:04 AM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CAPR 7.61 -0.06(-0.78%)
Will CAPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAPR
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Other News for CAPR
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate ...
Biotech stocks rise following Prasad exit from FDA
12 Health Care Stocks Moving In Wednesday's Intraday Session
Capricor Therapeutics (CAPR) Sees Increased Bullish Options Activity
Capricor Therapeutics call volume above normal and directionally bullish